Investors search for a winner in the vaccine race
It’s not just about who’s first, but about who can deliver
The race to develop a COVID-19 coronavirus vaccine is on. There are literally around 100 companies globally as well as numerous government organizations all rushing to get an effective and safe COVID-19 vaccine approved and ready for widespread use. After developing a vaccine comes testing (including 3 phases of human trials with bigger numbers in each phase), then FDA approval in the U.S., and finally production. Normally this process can take up to 10 years, but with the personal and global economic challenges of COVID-19, the goal is to have an effective and safe vaccine in 1-2 years, with the leading companies now moving into phase 3 human trials.
For investors the key question is which companies will win the race to produce a safe and effective vaccine, stopping the pandemic and allowing the global economy to return to some form of normality. Certainly with global cases at a staggering 20,810,774 and 746,411 deaths, the world desperately needs a cure. Worst hit countries are currently the USA, Brazil and India.
Cumulative global COVID-19 cases by country as of August 12, 2020 Source: www.worldometers.info
Today I look at which countries and companies are leading the COVID-19 vaccine race to see what may happen next.
Russia
The world’s press lit up this past week with Russia’s President Putin’s statement that Russia hasregistered the world’s first Covid-19 vaccine, named ‘Sputnik V’. While this was met with some skepticism and perhaps jealousy by the West, it appears that Russia is very well advanced and experienced with vaccines and in fact may likely end up with the world’s first COVID-19 vaccine, in part due to their fast-tracked testing process. The Gamaleya vaccine (developed through the Russian Direct Investment Fund) began Phase 3 testing last week. Russian officials have said production is likely to start next month (Sept.) and the Health Ministry saidmass vaccinations could begin by October, 2020.
The bigger question is who outside of Russia will use it? I highly doubt the western world will choose a Russian vaccine over a western vaccine. Some industry bodies have called the Russian Covid-19 vaccine a Pandora’s Box due to the shortened testing and the risks that come with it.
China
Many see China leading the global vaccine race. Reuters recently reported: “Chinese ventures are leading at least eight of the 26 global vaccine development projects currently testing on humans.”
China’s leading COVID-19 vaccine company is Sinovac Biotech Ltd. with their ‘CoronaVac’ vaccine. Their phase 3 trial in Indonesia with 1,620 human subjects is expected to end by December 2020. Sinovac’s vaccine candidate is also being tested in other places around the world, including phase 3 trials in Brazil.
Last week it was announced that Shenzhen Kangtai Biological Products (SHE: 300601) will produce AstraZeneca Plc’s prospective COVID-19 vaccine in mainland China (100m doses). A big plus for AstraZeneca to potentially gain access to the 1.4 billion person Chinese market.
Vaccine tracker timeline Source: Bloomberg
UK/Europe
Two of the big four global vaccine companies are headquartered in the UK or Europe. GlaxoSmithKline (GSK) is in the UK and Sanofi (SNY) is in France. Both will likely be front runners in Europe come late 2020 and they may even develop ajoint venture vaccine. AstraZeneca (AZN) is the other main competitor who is headquartered in the UK.
USA
The final two of the big four global vaccine companies are Pfizer (PFE) and Merck (MRK), both headquartered in the USA. In June it was reported that Trump “has selected its COVID-19 vaccine (five) finalists for Operation Warp Speed“. Naturally, four of the five are headquartered in the USA – Pfizer, Merck, Johnson & Johnson (JNJ) and Moderna (MRNA). The fifth was AstraZeneca. The goal of Operation Warp Speed is to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021.
In terms of funding, the US government has given massive support to the following companies:
March 30: HHS (U.S. Department of Health and Human Services) announced $456 million in funds for Johnson & Johnson’s candidate vaccine, with Phase 1 clinical trials set to begin this summer. April 16: HHS made up to $483 million in support available for Moderna’s candidate vaccine, which began Phase 1 trials on March 16 and received a fast-track designation from the FDA. May 21: HHS announced up to $1.2 billion in support for AstraZeneca’s candidate vaccine, developed in conjunction with the University of Oxford. The agreement is to make available at least 300 million doses of the vaccine for the United States, with the first doses delivered as early as October 2020 and Phase 3 clinical studies beginning this summer with approximately 30,000 volunteers in the United States. May 12: DoD and HHS announced a $138 million contract with ApiJect for more than 100 million prefilled syringes for distribution across the United States by year-end 2020, as well as the development of manufacturing capacity for the ultimate production goal of over 500 million prefilled syringes in 2021.
Source: HHS.gov Fact Sheet
More recently, on August 11, 2020 President Trump announced a deal with Moderna for 100 million doses of coronavirus vaccine, said to be worth US$1.53b.
US vaccine spending – Trump’s vaccine deals Source: Bloomberg – Vaccine for All ‘Decent Amount’ of Weeks Away
India
India is already a world-leader in vaccine production, currently producing ~60% of global vaccines. The Serum Institute of India may also do well as they have the world’s largest vaccine manufacturing facility and they are now preparing to be capable of producing1 billion COVID-19 vaccine doses pa. The Serum Institute already has a deal to produce a billion doses of a COVID-19 vaccine being developed by the University of Oxford and AstraZeneca. This places AstraZeneca in a very strong position to be able to reach the largest scale of all vaccine competitors.
COVID-19 vaccines are already in phase 3 human trials in many parts of the world For an in depth list, top 5, and daily stock price performance of the global vaccine companies investors can search the daily InvestorIntel watchlists here.
InvestorChannel’s Covid-19 Watchlist Update for Wednesday, August 12, 2020
Source: InvestorChannel’s Covid-19 Watchlist Update
Closing remarks For now it looks like the Russians may beat the Chinese and be first to market with a COVID-19 vaccine, followed by the USA then Europe. This could happen as early as October or November this year, but will take time to scale up production, and there my be lingering questions about efficacy and safety. My view is that it will not matter so much who is first.
What will mater is where will countries buy their vaccine. I think the answer to this is fairly clear. Countries will buy first from their own national companies if possible, then after that from ally countries. The US will buy its vaccine not from Russia or China, but from US companies or US allies. We have already see this with President Trump announcing several deals and his top 5 companies (four from USA, one from UK) in Operation Warp Speed.
For investors it probably won’t matter who wins the vaccine race, but more who can profit from it. The drug companies with good vaccines and more importantly good connections to wealthy countries (US, Europe, UK) and governments will be the likely financial winners.
While much is already priced in, the likely winners should be Moderna (US deal already for 100m doses), Pfizer Inc., Merck, Johnson and Johnson, and AstraZeneca Plc (which has a manufacturing capacity of 1b doses pa arranged with Serum, plus 100m in China). All have have begun late-stage testing for Covid-19 vaccines with initial results from some of the human trials expected in October/November. So we may start see a western vaccine as soon as November or December, with production scaling up in 2021. Rapid and accurate testing the key to a return to normalcy
And here are three companies working on it.
Imagine a global pandemic caused by a new virus. Apparently it has been around for 6, 8 or 10 months and may or may not have come from China (depending on which expert is talking on any given day).
The symptoms are multiple (and variable and inconsistent between infected people, or so it seems) and the test for it is a long nasal swab inserted into your body that is uncomfortable at best but usually quite painful.
Then imagine that the test results (none of which may be accurate) take 2-6 days and may come back as:
Positive Negative False Positive False Negative
Oh, and apparently, there is also a blood test for antibodies which would tell you if you had the virus… but actually there are many (unreliable) blood tests that may produce the same range of four results as above.
Exhausted yet? We all are, as the current pandemic has set the world on its ear, crippled the global economy and created an undeniable environment of fear.
However, there are glimmers of hope for accurate testing which would allow the world to get back to an almost pre-virus life. Instead of waiting days for suspect results, companies are focusing on technology using quick, accurate, inexpensive and technologically proven procedures that do not require highly trained staff or expensive equipment.
Three Canadian public companies are at the forefront of developing these new, non-invasive, technology driven coronavirus tests that will be accurate, eliminate (mostly) the need for that sketchy nasal swab, and provide nearly instant, accurate results.
Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF)
The newest entrant in the public markets, Sixth Wave began trading in February 2020 after a previous merger with another public company and subsequent financings, etc. Current market capitalization is approximately C$26 million.
Sixth Wave is a development stage nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Accelerated Molecularly Imprinted Polymers (AMIPs). Since every substance has a unique size, shape and chemical properties, these attributes can be utilized at the individual molecule level to create highly efficient adsorption/detection media to solve problems that cannot be solved with conventional means.
What does this mean? In simple terms, they can detect anything at the molecular level and this technology has already been successfully deployed in both the cannabis and gold mining industries. In practical terms, by using AMIPs, Six Wave’s technology could be used to detect COVID-19 in airborne, water and wastewater environments. Further, successful development of their technology could also be rolled out to provide accurate, almost immediate testing for the coronavirus in individuals.
Sixth Wave (along with its partners) recentlyreceived approval from the Natural Sciences and Engineering Research Council of Canada to advance virus detection technology testing using AMIP. Successful testing could optimistically be completed before year-end with an available product possible for market in early 2021. A publicly available product could be as simple as a face mask that changes colour if positive for COVID-19.
Sona Nanotech Inc. (CSE: SONA | OTCQB: SNANF)
Sona Nanotech is a well-established public company whose technology development of gold nanorods started back in 2013. The company went public in 2018 and has a current market capitalization of approximately C$677 million, although this has jumped dramatically since February 2020 as a result of the coronavirus pandemic.
Gold nanorods have multiple uses, but the potential for providing near-instant results has very much excited the market. Using lateral flow assay technology testing (comparable to a home pregnancy test), a positive or negative test for coronavirus can be determined without the need for specialist lab equipment or operators. In April 2020, Sona tested a working prototype of the test in a hospital laboratory environment with live, COVID-19 patient samples, achieving positive results. Further testing is underway and of course government approvals will be required
The company’s analytical test still requires the dreaded nasal swab for the evaluation source material, but results should be more accurate and available in minutes.
XPhyto Therapeutics Corp. (CSE: XPHY | OTC: XPHYF | FSE: 4XT) Originally created for the cannabis industry,Xphyto Therapeutics has subsidiaries in Alberta and in Germany. Established in late 2017, the company went public in mid-2019 and has a current market capitalization of approximately C$190 million. The company had a strong share price prior to the coronavirus pandemic due to its other products, but application of related technology has caught the market’s attention.
Since starting in the cannabis space, the company has branched out in Germany with strategic acquisitions/development agreements in diagnostics and therapeutic films. In part due to the arrival of the coronavirus pandemic, the company first initiated an infectious diseases program in February 2020 which was directly transferable to developing a low-cost, “real time” oral pathogen screening platform for COVID-19 in March 2020. By July, the company had confirmed successful function of its proprietary COVID-19 RNA probes and its universal coronavirus RNA probes in prototype lateral flow assay testing. Visual confirmation of test results was observed in five to seven minutes.
Short of an actual vaccine, rapid and accurate testing continues to be the Holy Grail in the world-wide response to COVID-19 and the key to a return to economic and social normalcy. These are among the companies to watch with innovative testing technologies.
Don Bubar on Avalon’s 20 years in rare earths and their diversified asset base of critical materials
“We have been in rare earths business for over 20 years now,” Don Bubar, President, CEO and Director ofAvalon Advanced Materials Inc. (TSX: AVL | OTCQB: AVLNF), tells InvestorIntel’s Tracy Weslosky in an interview. “And we are very well known among investors in the US for our lead role in the rare earths bubble 10 years ago. Whenever there is new development and news headline related to the risk on security of supply, then you will see speculative trading activity in Avalon.”
“Our strategy has been to have a diversified asset base,” Bubar continued. “That gives us exposure to broad range of these new emerging critical materials. We are basically positioned to react to when there is a new demand in the marketplace.”
Bubar went on to say that Avalon is working with a partner on its Nechalacho rare earth elements property and has maintained its main resource for any future upside. “We continue to look at other possibilities to create new rare earths supplies, by looking at how we can use new technology to recover rare earths from non-traditional sources such as historic mine wastes,” he said.
Bubar also commented on Avalon’s Separation Rapids Lithium Project: “Our focus now is on taking advantage of the opportunity in lithium markets. We are permitted now to recover a bulk sample to finalize our process flowsheet, do a pilot plant run and produce some product samples for customers who have expressed interest in the product in the glass industry as well as start to revisit serving the battery materials market going forward.”
To access the complete interview, click here.
Disclaimer: Avalon Advanced Materials Inc. is an advertorial member of InvestorIntel Corp.
Fission Uranium’s President on why the uranium bull market starts now
“Demand continues to grow as supply constricts”
Uranium prices continue to recover in 2020 leading to renewed hope for the uranium sector after some very tough years. The US appears to be close to finalizing a US uranium reserve and the associated $150m a year funding as well as perhaps taking a tougher stance on overseas subsidized uranium from Russia and Kazakhstan. Should these trends continue, many are wondering are we in the start of a uranium bull market.
In an exclusive interview with InvestorIntel, Fission Uranium President & COO Ross McElroy said, “I think we are in the start of a bull market right now. That’s happened because there’s been so many production shutdowns globally. All the major mines, even all the production in Canada has been shutdown. So, we know the demand is there and it continues to grow, supply is constricting and these are the things that are making the bottom of the bull market happen.” Fission Uranium Corp. (TSX: FCU | OTCQX: FCUUF)
Fission Uranium Corp. (“Fission”) is 100% owner of the Patterson Lake South (PLS) property, located in Canada’s Athabasca Basin, home to the world’s richest uranium mines. The PLS Property comprises 17 mineral claims totaling 31,039 ha located on the southwest margin of the Athabasca Basin. The Project is host to the award winning Triple R deposit – the most significant high-grade, near-surface project in the region. Fission has also discovered two other major, high- grade zones and has outlined the largest mineralized trend in the region.
The Triple R Deposit has 102,360,000 lbs. U3O8 Indicated Mineral
Resource @2.10% U3O8 and 32,810,000 lbs. U3O8 Inferred Mineral
Resource @1.22% U3O8.
The Triple R deposit longitudinal cross section showing the resource starting 50m underground
Source: Company presentation The Triple R deposit remains open, and the PLS property has excellent exploration potential as ~80% of the property has yet to be explored. The deposit has substantial high-grade mineralization starting just 50m from surface.
The 2019 PFS had two scenarios. For the underground-only mine PFS scenario, the post-tax NPV8% was C$702m, post-tax IRR was 25%, and the initial CapEx was C$1,177m. Operating costs were estimated at a very low C$9.57/lb U3O8 (US$7.18) over a 7 year mine life.
Given the current uranium price of US$32.25 that would make the Triple R Project very profitable once established. Of course, further drilling will be required to build up the level of uranium reserves and extend the mine life. Given the success to date and the 80% yet unexplored, the odds favour of Fission achieving this over time. A higher uranium price and longer mine life could certainly help boost the Project’s NPV.
Fission Uranium’s Triple R Project PFS summary shows very low uranium costs of production in both scenarios Source: Company presentation
Fission Uranium is now working on permitting, EIS, and a Feasibility Study. The company is well funded to achieve the above next steps after a recent raise.
Fission Uranium is backed by China’s CGN Mining, which has invested over $82m in Fission to date. More recently legendary mining investor Eric Sprott provided Fission with aUS$10 million senior secured Credit Facility at 10% pa for 4 years. This shows that Sprott has confidence in the value of the resource and/or the Company’s ability to service and pay back the Facility. In connection with the Facility, Fission has agreed to issue 20,666,667 common share purchase warrants to Sprott and its affiliates.
Closing remarks
With a uranium bull market possibly in the early stages, Fission Uranium looks well placed to continue to attract funding and grow their resource, thereby boosting their NPV in subsequent Feasibility Studies. The high CapEx remains a challenge to be funded but given the pedigree of past funding, and the very high quality resource, it should ultimately be achievable. Certainly the Western world is now looking much closer to home to secure their supply chains of critical materials such as uranium.
Fission Uranium is currently trading on a market cap of C$190m. Investors will need some patience but should benefit from a tailwind or positive news flow in the uranium sector led by US developments that are expected to unfold in the near term.
Ur-Energy stands ready to supply future US uranium reserve
U.S. legislation on the table to reduce foreign dependency
As the US struggles to finalize their new uranium funding to build a significant US uranium reserve using the previously announced US$150 million U.S. uranium reserve program, two new Acts have recently gone to US legislators.
On July 29, 2020, legislation was introduced in the House of Representatives by Representatives Cheney and Latta to establish a National Uranium Reserve. Then on July 30, 2020, U.S. Senator Barrasso, Chairman of the Senate Committee on Environment and Public Works, introduced the American Nuclear Infrastructure Act of 2020. Among other items, it includes the authorization to create a uranium reserve to fuel America’s nuclear reactors with domestic fuel and bolster America’s uranium industry.
The last 4 years of low uranium prices has led to significant uranium supply destruction to the point where demand for new uranium will likely put a floor on uranium prices and keep them from falling back again. The uranium miners who survived stand to benefit as the cycle turns positive.
Uranium prices from 1989 to today – Currently at USD 32.25
Source: Trading Economics
Today I look at one US uranium miner who is well placed to prosper.
Ur‐Energy Inc. (NYSE: URG | TSX: URE) is one of only two primary US uranium producers still operating able to bring on new uranium supply with a globally competitive cost of production. Ur-Energy’s flagship project is the Lost Creek Property in Wyoming. They also have several other uranium projects including Shirley Basin and Lost Soldier.
There are two key aspects investors should know about Ur- Energy:
1. They already have a competitive cost of uranium production and a large and growing uranium reserve/inventory. 2. They have the ability to rapidly expand uranium production if needed.
Ur-Energy continues to build up their uranium inventory ready for anticipated US Reserve purchases
In Q2, 2020 Ur-Energy produced 4,119 pounds of U3O8 at the Lost
Creek plant, of which 2,892 pounds of U3O8 were packaged in drums. Inventory at the converter totaled approximately 268,552 pounds at June 30, 2020. In 2020 Q2, Ur-Energy sold 167,000 purchased pounds under a term contract at an average price of $41.50 per pound. The 167,000 pounds were purchased at a weighted average cost of $26.01 per pound. There were no sales of produced inventory in the first six months and we do not anticipate any sales of produced inventory in 2020.
Ur-Energy has the ability to quickly expand their uranium production from Lost Creek
Ur-Energy is prepared to rapidly expand uranium production at Lost Creek, to an annualized run rate of one million pounds. They can also bring on their other projects, albeit with a time lag.
For investors new to Ur-Energy, what is happening here is that the Company is building up their inventory of uranium, while still meeting their long term contracts. This inventory would be perfectly suited to sell to a US uranium reserve if and when purchases begin, ideally at higher prices.
Drilling for uranium at Ur-Energy’s Lost Creek Property Source
On August 5, 2020 Ur-Energy stated in their Q2, 2020 earning release:
“Following multiple announcements of industry production suspensions and reductions earlier this year, U3O8 spot prices increased nearly 33 percent to $33 per pound in June. U3O8 spot prices have traded between $32 and $34 per pound since April. The production cuts amount to as much as 46 million pounds of primary production on an annualized basis and are expected to widen the supply deficit as global demand continues to grow.”
Ur-Energy also stated:
“In July 2020, Energy Secretary Brouillette told the House Energy and Commerce Subcommittee on Energy that DOE is working to end U.S. reliance on Russia for nuclear fuel. DOE wants to process American-sourced uranium into high-grade fuel at the DOE facility in Portsmouth, Ohio next year. Centrifuges have been moved from DOE’s Oak Ridge laboratories to Portsmouth. Additionally, DOE is working with lawmakers to authorize the creation of the uranium reserve.” Closing observations
The US uranium miners can see the light at the end of the tunnel, even if they are not there yet. The US government continues to progress – if slowly – towards establishing a secure uranium supply. Two new Acts have helped build pressure on the U.S. House Committee on Appropriations who are yet to allocate the Department of Energy’s previously recommended US$150m of funds.
Meanwhile the global uranium supply destruction has pushed uranium prices higher, and in time the US government will surely finalize and release the funding for the proposed US uranium reserve.
The game of patience continues for investors, and leading US uranium companies such as Ur-Energy remain on hold and attractively valued due to the uncertainty. Just remember, patience is a virtue.
Demand for dynaCERT clean technology drives company forward
Cashed up, ramped up production line, and senior listed
Vehicle emissions are universally recognized as an environmental concern, especially diesel emissions which the WHO has linked with causing cancer. Governments all over the world are continually tightening their emission standards. In 2020 both Europe and China made significant moves to reduce vehicle emissions. Once company in particular has the potential to be winner from the huge trend to reduce diesel emissions. dynaCERT Inc. (TSX: DYA | OTCQX: DYFSF) manufactures, distributes, and installs its Carbon Emission Reduction Technology (CERT) for use with diesel engines. Their flagship product is HydraGEN™, an electrolysis unit that produces H2 and O2 gases to optimize the diesel fuel burn, resulting in a 6-19% increase in fuel economy and a50%+ reduction in emissions.
Founded in 2004, dynaCERT has spent the last 16 years developing their patented technology and has only recently begun to commercialize it on a large scale. dynaCERT’s technology can be used in diesel engines in on-road vehicles, reefer trailers, off-road construction, power generation, mining and forestry equipment, marine vessels, heavy equipment, and railroad locomotives. dynaCERT’s HydraGEN™ unit installed on a semi to reduce emissions and boost efficiency Source: Company investor presentation dynaCERT recently completed an oversubscribed equity raising at C$0.68 (included a half warrant per share raised, exercise price of $1.00 for a period of 24 months). Demand was such that the raise was upsized to $8,367,400. The funds will be used to finance raw materials and manufacturing and assembly costs to create and deliver finished goods as well as for working capital and general corporate purposes. Five major firms in the Canadian financial community participated in dynaCERT’s over-subscribed, over-night-marketed, equity financing. dynaCERT receives two stock market exchange upgrades in two months dynaCERT now trades on a market cap of C$218m. As a result of their success dynaCERT has recently been upgraded on not one, but two exchanges. In July dynaCERT was upgraded from the TSX Venture Exchange (TSXV) to the main board TSX in Canada. This follows their June upgrade to the OTCQX from the OTCQB Venture Market in the USA.
Commenting on the US upgrade, the company said:
“The OTCQX Market is designed for established, investor- focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.”
Moving forward quickly: dynaCERT re-opens and upgrades their HydraGEN™ assembly plant on August 4, 2020
In a July 30, 2020 dynaCERT announced that their assembly line had been retrofitted with a new semi-automated assembly system, “to provide improved high standards instate-of-the-art technical specifications” able to maintain a capacity of 100 units per day or 2000 units per month with a single 8-hour shift per day. dynaCERT said that their new capacity “is expected to be capable of tripled production of 6,000 units per month using three shifts per day.” dynaCERT has the following global partners/dealers:
MOSOLF is one of the largest truck servicing companies in Europe with installations & 23 showrooms throughout Europe. They have distribution channels in Germany, France, Netherlands, Belgium, Luxembourg, Poland, Czech Republic. Farhi Holdings – A distributor for Brazil & Israel. H2 Tek – Has a focus on mining with mining projects in: Canada, USA, Peru, Chile, Brazil, Paraguay, Uruguay, Argentina, Russia, Mongolia, and Australia. KarbonKleen was awarded the exclusive dealership rights in the trucking industry in the USA until December 31, 2024 (subject to certain quotas of a minimum of 150,000 HydraGEN Technology units over a little more than 3 years). On May 9, 2020, it wasannounced that KarbonKleen achieved a purchase order for 3,000 HydraGEN™ Technology units. KarbonKleen also has financing for a Mexico assembly with an MOU for 1,000,000 units. dynaCERT’s sales and revenue now have the ability to rise rapidly boosted by added cash reserves, their upgraded production facility, and a growing sales pipeline from their large and growing network of dealers. dynaCERT now has~40 dealers around the world selling their products to small and large truck owners, fleets, and government organisations that use diesel engines. With a billion diesel engines in the world, dynaCERT’s green emission technology is in big demand. Last week dynaCERT expressed that unlike many industries, they were well positioned for growth even in these challenging times:
“The Company has re-emerged from the global COVID-19 economic slowdown with a cleaner and stronger balance sheet, having more than adequate cash reserves, a very strong balance sheet with approximately $18,000,000 in cash and virtually no significant debt, a better Assembly Plant, an improved R&D facility, significant Product improvements and a continued backlog of previously announced purchase orders. The Sales Department of the Company continues to maintain existing dealer relationships and has added new dealers where global marketing continues to be active.”
Added to this was a note that the Company’s products can now be offered to numerous markets in Dubai and other parts of the UAE and the Middle East.
Strong growth in dynaCERT’s revenue Source: Yahoo Finance
Closing remarks dynaCERT is making all the right moves in leveraging the increasing demand to reduce diesel emissions and to improve fuel economy. The Company is rapidly growing their distribution networks and achieving impressive sales, increasing revenues, successfully raising over C$8m in an oversubscribed/overnight equity raise, recently upgraded by two stock exchanges, and have upgraded their assembly plant to meet demand (full capacity is now a potential 6,000 units/month). Even legendary mining investor Eric Sprott is onboard and owns a 8.66% share of the Company.
The trend is becoming very clear that dynaCERT is on track to become a much larger company as the demand for their emissions reducing technology is enormous. As economies of scale kick in so should profits. For investors, dynaCERT is still looking reasonably priced assuming the forecast future revenues are achieved. Dr Gluckman on the rapid- detection benefits of Sixth Wave’s virus test kits
“You can think about our polymer almost like an antibody inside a body,” says Dr. Jonathan Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF), in an interview with InvestorIntel’s Tracy Weslosky. “A virus has a size and shape and we create an imprint in our polymer for that exact virus. Then we will detect that directly based on our chemistry,” he continued. “We are working to integrate this into masks and breathalyzers and then we can just utilize the breath, as we all know that’s the main transmission method. If you think about putting a mask on, not only will that mask provide protection, it can also, right there, be the test for COVID-19.”
Dr. Gluckman explained that Sixth Wave’s COVID-19 detection technology is currently under development but the company has successfully launched and commercialized other products with similar properties. The company has received a grant from the Canadian government to work with York University and the CTRI (Centre Technologique des Résidus Industriels) to use its virus detection technology to detect COVID-19 virus in wastewater supplies and in air handling systems.
Highlighting the advantages of Sixth Wave’s COVID-19 test over other tests, Dr. Gluckman also said that the test will be cheaper, faster and easy to use.
To access the complete interview, click here.
Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.